BIOAHealthcare · Drug Manufacturers - Specialty & GenericThe 9 Wall Street analysts covering BioAge Labs, Inc. hold a median 12-month price target of $30 — +252.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 12 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores BioAge Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (70): Analysts have, on balance, been raising their forecasts.
Volatility (16): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BIOA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +252.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | Roth Capital | Reiterates | Buy | $25 |
| 8 Sept 2026 | BTIG | Reiterates | Buy | $40 |
| 6 Aug 2026 | BTIG | Reiterates | Buy | — |
| 6 Aug 2026 | BTIG | Reiterates | Buy | $40 |
| 3 Aug 2026 | BTIG | Reiterates | Buy | — |
| 3 Aug 2026 | BTIG | Reiterates | Buy | $40 |
| 31 July 2026 | Needham | Maintains | Buy | — |
| 31 July 2026 | Needham | Maintains | Buy | $50 → $35 |
| 27 May 2026 | Roth Capital | Initiates | Buy | $36 |
| 27 May 2026 | Roth Capital | Initiates | Buy | — |
| 13 May 2026 | BTIG | Initiates | Buy | — |
| 27 Mar 2026 | Needham | Initiates | Buy | — |
| 10 Mar 2026 | Citigroup | Maintains | Buy | — |
| 25 Feb 2026 | Oppenheimer | Initiates | Outperform | — |
| 18 Feb 2026 | Jefferies | Upgrade | Buy | — |
| 27 Jan 2026 | Piper Sandler | Initiates | Overweight | — |
| 8 Dec 2025 | Morgan Stanley | Upgrade | Equal-Weight | — |
| 29 Oct 2025 | Citigroup | Maintains | Buy | — |
| 22 Oct 2025 | Citigroup | Upgrade | Buy | — |
| 24 Mar 2025 | Citigroup | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIOA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, BioAge Labs, Inc. returned +73.1% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 70% of US stocks
Cheaper than 7% of US stocks
Cheaper than 72% of US stocks
Cheaper than 65% of US stocks
Higher than 31% of US stocks
Higher than 38% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 28% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BioAge Labs, Inc. has a market value of $390.1M and an enterprise value of $73.8M.
Revenue in the twelve months to 30 June 2026: $10.4M. The latest quarter grew 1.6% year on year.
Net income over the same four quarters: −$94.5M, a −912.3% net margin.
Free cash flow in the twelve months to 30 June 2026: −$88.1M.
Trailing P/E: 1.4×; forward P/E: −3.5× — the forward figure prices analyst consensus estimates, not reported earnings.
BioAge Labs, Inc. employs 60 people — $173K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BioAge Labs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
BioAge Labs, Inc. presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation made available via Seeking Alpha.
Why it matters — BIOA watchers would care because investor presentations at major conferences offer insight into the company's pipeline and strategy.
BioAge Labs announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102, a novel NLRP3 inhibitor, in adults with diabetic macular edema. The approximately 180-participant trial will evaluate BGE-102 as monotherapy and in combination with anti-VEGF therapy, with topline results expected in the second half of 2027.
Why it matters — This milestone advances BioAge's BGE-102 program in diabetic macular edema and will inform its development strategy in other NLRP3-driven retinal diseases, including geographic atrophy, potentially broadening its pipeline beyond cardiometabolic indications.
BioAge Labs' shares fell over 40% partly due to a sell-off triggered by rivals' data, despite competitive Phase 1 results for its NLRP3 inhibitor BGE-102, which achieved up to 98% IL-1β suppression and 86% median hsCRP reduction. The article views the sell-off as overblown, citing Phase 2 topline data expected in H2 2026 and a diversified pipeline of ophthalmology, apelin-APJ programs, and partnerships with Novartis and Eli Lilly.
Why it matters — A BIOA watcher would care because the item frames the recent stock drop as an overreaction, highlighting expected Phase 2 data for BGE-102 in H2 2026 and a diversified pipeline and partnerships that support long-term optionality.
BioAge Labs announced that it will participate in several upcoming investor conferences. The clinical-stage biotechnology company develops therapeutic candidates for cardiometabolic diseases by targeting the biology of human aging.
Why it matters — Conference participation gives investors and analysts additional opportunities to hear updates about BioAge's pipeline and strategy.
BioAge Labs reported a quarterly loss of $0.58 per share for Q2, narrower than the Zacks Consensus Estimate of a $0.65 loss and slightly better than the $0.6 per-share loss a year ago. The company also beat revenue estimates.
Why it matters — A BIOA watcher would care because the company's quarterly loss came in better than analyst expectations, indicating results were stronger than consensus forecast.
The 9 Wall Street analysts covering BioAge Labs, Inc. have a median 12-month price target of $30, with estimates ranging from $20 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering BioAge Labs, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioAge Labs, Inc. 40 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, BioAge Labs, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (70 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +252.9% from the last close, and Ticker Nerd's factor model ranks BioAge Labs, Inc. 40 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BioAge Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIOA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $73 over the next 12 months.
BioAge Labs, Inc. returned +73.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases by targeting the biology of human aging.
The most recent item we track (Seeking Alpha, 9 Sept 2026): "BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript". BioAge Labs, Inc. presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation made available via Seeking Alpha.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases by targeting the biology of human aging. BioAge Labs, Inc. advances a pipeline of product candidates designed to address conditions such as obesity and other age-associated disorders, using human data and molecular insights to identify drug targets linked to healthy aging. Its current programs include orally available small-molecule candidates and inhibitors aimed at cardiometabolic and neuroinflammatory disease pathways. The company’s work spans therapeutic development in obesity, cardiovascular risk, retinal disorders, and other metabolic indications, positioning it as a research-driven participant in the biotechnology sector. BioAge Labs, Inc. operates with a translational approach that connects aging biology to drug discovery, supporting the development of medicines intended to treat diseases with common biological mechanisms.
CEO Dr. Kristen Fortney Ph.D. · 60 employees · United States · https://bioagelabs.com
